Ipilimumab – Uses, Dosage, Side Effects, Interaction Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma. Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approval on 25 March 2011.[rx] Mechanism of action Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.[rx] T lymphocytes can recognize and destroy cancer cells. However, an inhibitory mechanism interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and allows the lymphocytes to continue to destroy cancer cells.[rx] Cancer cells produce antigens, which the immune system can use to identify them. These antigens are recognized by dendritic cells that present the antigens to cytotoxic T lymphocytes (CTLs) in the lymph nodes. The CTLs recognize the cancer cells by those antigens and destroy them. However, along with the antigens, the dendritic cells present an inhibitory signal. That signal binds to a receptor, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), on the CTL and turns off the cytotoxic reaction. This allows the cancer cells to survive.[rx] Ipilimumab binds to CTLA-4, blocking the inhibitory signal, which allows the CTLs to destroy the cancer cells. In 2014 a study indicated that the antibody works by allowing the patients’ T cells to target a greater variety of antigens rather than by increasing the number attacking a single antigen.[rx] or Ipilimumab is a CTLA-4 monoclonal antibody.[rx] Two signals are necessary for full T-cell activation: major histocompatibility complexes (MHC) I and II receptors on T-cells binding to tumor-associated antigens (TAA) presented by antigen-presenting cells (APCs) as well as CD28 receptor located on the T cell binding to CD80 and CD86 (B7 ligand subtypes) on APCs. These two signals result in T-cell proliferation and cytokine release, triggering and amplifying the immune response. In response to this T-cell activation, cytotoxic T lymphocyte antigen-4 (CTLA-4) becomes upregulated, competing with CD28 for CD80 and CD86 binding on APCs. However, with a much higher affinity, it can downregulate the T cell activation, which results in a decreased immune response to TAAs. CTLA-4 is the primary negative regulator of T-cell-mediated antitumor immune responses and therefore represents a critical checkpoint for immunity, controlling both the intensity and duration of an immune response. Ipilimumab is an anti-CTLA-4 monoclonal antibody that prevents CD80 and CD86 on APCs from binding to CTLA-4 on T cells. This blockage of CTLA-4 signaling allows T-cell activation, proliferation, and amplification of T-cell-mediated immunity, which allows the patient’s immune system to mount a better response.[rx] The drug is metabolized via the CYP450 enzyme system and has a half-life of 15.4 days. Indications Ipilimumab is indicated in the following cancerous conditions: Melanoma Treatment of unresectable or metastatic melanoma in patients ≥12 years old Treatment of unresectable or metastatic melanoma, in combination with nivolumab, in adult patients Adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of >1 mm who have undergone complete resection, including total lymphadenectomy Renal Cell Carcinoma (RCC) First-line treatment of patients with intermediate- or poor-risk advanced renal cell carcinoma in combination with nivolumab Colorectal Cancer In combination with nivolumab, treatment of patients ≥12 years old with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following previous treatment with a fluoropyrimidine, oxaliplatin, and irinotecan Hepatocellular Carcinoma In combination with nivolumab, treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib Non-Small Cell Lung Cancer (NSCLC) Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1, with no EFGR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab Treatment of adult patients with metastatic or recurrent non-small cell lung cancer, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy Malignant Pleural Mesothelioma Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab Esophageal Cancer – Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab Cutaneous Melanoma Hepatocellular Carcinoma Metastatic Esophageal Squamous Cell Carcinoma Metastatic Melanoma Metastatic Non-Small Cell Lung Cancer Microsatellite Instability High Metastatic Colorectal Cancer (CRC) Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC) Non-small Cell Lung Cancer (NSCLC), Recurrent Unresectable Melanoma Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC) Unresectable Malignant Pleural Mesothelioma (MPM) Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC) Use in Cancer Ipilimumab is approved to treat: Colorectal cancer in adults and children aged 12 years and older. Ipilimumab is used with nivolumab to treat metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer that got worse after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan hydrochloride.¹ Esophageal cancer that cannot be removed by surgery or has spread to other parts of the body. Ipilimumab is used with nivolumab as the first treatment in adults with squamous cell carcinoma of the esophagus. Hepatocellular carcinoma (a type of liver cancer). Ipilimumab is used with nivolumab in patients who have already been treated with sorafenib.¹ Malignant pleural mesothelioma. Ipilimumab is used with nivolumab as the first treatment in adults whose cancer cannot be removed by surgery. Melanoma. Ipilimumab is used alone to help prevent melanoma from coming back after surgery to remove melanoma in the skin and lymph nodes. Ipilimumab is used in alone or with nivolumab in adults and children aged 12 years and older whose cancer cannot be removed by surgery or has spread to other parts of the body. Non-small cell lung cancer. Ipilimumab is used with nivolumab as the first treatment in adults with: Cancer that has spread to other parts of the body and has the PD-L1 protein but does not have a mutation in the EGFR or ALK gene. Cancer that has spread to other parts of the body or has come back and does not have a mutation in the EGFR or ALK gene. It is used with platinum chemotherapy. Renal cell carcinoma (a type of kidney cancer) that is advanced. Ipilimumab is used with nivolumab in some patients with renal cell carcinoma as the first treatment. This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that ipilimumab provides a clinical benefit in these patients. Ipilimumab is also being studied in the treatment of other types of cancer. Contraindications overactive thyroid gland a condition with low thyroid hormone levels pituitary hormone deficiency severely decreased function of cortex of adrenal gland encephalitis a painful condition that affects the nerves in the legs and arms called peripheral neuropathy a disorder of the peripheral nerves that enable movement called peripheral motor neuropathy Guillain-Barre syndrome myasthenia gravis, a skeletal muscle disorder detachment of the retina of the eye a type of inflammation of the lung called interstitial pneumonitis inflammation of the small and large intestine acute inflammation of the liver acute inflammation of the pancreas bleeding of the stomach or intestines kidney inflammation high amount of bilirubin in the blood abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding multifocal motor neuropathy Dosage Strengths: 5 mg/mL Dosing by indication is as follows: Melanoma As adjuvant treatment: 10 mg/kg/dose IV every three weeks for 4 doses, then commencing with the 24th week, the dose changes to 10 mg/kg/dose IV every 12 weeks for up to three years. For metastatic or unresectable disease: 3 mg/kg/dose IV every 3 weeks for up to 4 doses; treatment must be completed within 16 weeks following the first dose. It can be used as monotherapy or with nivolumab.[rx][rx] Advanced Renal Cell Carcinoma 1 mg/kg/dose IV every 3 weeks for up to 4 doses. In patients with previously untreated disease or who have poor risk profiles, use with nivolumab.[rx] Metastatic Microsatellite Instability-high or Mismatch Repair-deficient Colorectal Cancer 1 mg/kg/dose IV every 3 weeks for up to 4 doses. In patients with relapsing or refractory disease, use in conjunction with nivolumab.[rx] Hepatocellular Carcinoma 3 mg/kg/dose IV every 3 weeks for up to 4 doses. In patients with disease that is refractory to treatment with sorafenib or who cannot tolerate sorafenib, use with nivolumab.[rx] Non-small Cell Cancer For metastatic PD-L1-expressing disease: 1 mg/kg/dose IV every 6 weeks for up to 2 years. This is a first-line treatment, along with nivolumab, for patients without EGFR or ALK genomic tumor defects. Recurring or metastatic disease: 1 mg/kg/dose IV every 6 weeks for up to 2 years. This is a first-line treatment, along with nivolumab plus two cycles of histology-based platinum-doublet chemotherapy, for patients without EGFR or ALK genomic tumor defects. Malignant Pleural Mesothelioma 1 mg/kg/dose IV every 6 weeks for up to 2 years; used with nivolumab.[rx] If the patient’s creatinine clearance is above 15, no dose adjustment is necessary. Dosing is undefined for patients with renal disease and creatinine clearance of 15 and lower. Patients with hepatic impairment with an AST reading between 1 to 1.5 times the upper normal limit require no dose adjustment. Dosing is undefined for patients with bilirubin values over 1.5 of the upper normal limit irrespective of AST value. For pediatric dosing, refer to institutional protocols; ipilimumab is only approved for children aged 12 and older. Ipilimumab may only be administered intravenously (IV), specifically with an IV line containing a sterile, low protein binding filter to minimize protein medication loss. It should be infused over 30 to 90 minutes.[rx] It should not be mixed or administered with any other medical products. No other specific or extra precautions are necessary. or Melanoma – Metastatic UNRESECTABLE OR METASTATIC MELANOMA: 3 mg/kg IV over 90 minutes every 3 weeks for a maximum of 4 doses ADJUVANT TREATMENT OF MELANOMA: 10 mg/kg IV over 90 minutes every 3 weeks for 4 doses followed by 10 mg/kg IV over 90 minutes every 12 weeks for up to 3 years For the treatment of unresectable or metastatic melanoma For the adjuvant treatment of cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy Renal Cell Carcinoma Ipilimumab 1 mg/kg IV over 30 minutes every 3 weeks with nivolumab 3 mg/kg IV over 30 minutes on the same day for 4 doses; after completing 4 doses of the combination, administer nivolumab as a single agent until disease progression or unacceptable toxicity Review the full prescribing information for nivolumab prior to initiation. For intermediate or poor risk, previously untreated advanced renal cell carcinoma (RCC) in combination with nivolumab Colorectal Cancer Ipilimumab 1 mg/kg IV over 30 minutes every 3 weeks with nivolumab 3 mg/kg IV over 30 minutes on the same day; after completing 4 doses of combination therapy, administer nivolumab as a single agent until disease progression or unacceptable toxicity Review the full prescribing information for nivolumab prior to initiation. In combination with nivolumab for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan Hepatocellular Carcinoma Ipilimumab 3 mg/kg IV over 30 minutes every 3 weeks with nivolumab 1 mg/kg IV over 30 minutes on the same day for 4 doses; after completing 4 doses of combination therapy, administer nivolumab as a single agent until disease progression or unacceptable toxicity Review the full prescribing information for nivolumab prior to initiation. In combination with nivolumab for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib Non-Small Cell Lung Cancer METASTATIC NON-SMALL CELL LUNG CANCER EXPRESSING PD-L1: Ipilimumab 1 mg/kg IV over 30 minutes every 6 weeks with nivolumab 3 mg/kg IV over 30 minutes every 2 weeks until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression METASTATIC OR RECURRENT NON-SMALL CELL LUNG CANCER: Ipilimumab 1 mg/kg IV over 30 minutes every 6 weeks with nivolumab 360 mg IV over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression; this is given with histology-based platinum-doublet chemotherapy every 3 weeks for 2 cycles Review the full prescribing information for nivolumab prior to initiation In combination with nivolumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (1% or greater) as determined by an FDA-approved test. with no EGFR or ALK genomic tumor aberrations In combination with nivolumab and 2 cycles of platinum-doublet chemotherapy for the first-line treatment of adult patients with metastatic or recurrent NSCLC, with no EGFR or ALK genomic tumor aberrations Malignant Pleural Mesothelioma Ipilimumab 1 mg/kg IV over 30 minutes every 6 weeks with nivolumab 360 mg IV over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression Review the full prescribing information for nivolumab prior to initiation. For the first-line treatment of unresectable malignant pleural mesothelioma in combination with nivolumab Pediatric Dose for Melanoma – Metastatic 12 years and older: UNRESECTABLE OR METASTATIC MELANOMA: 3 mg/kg IV over 90 minutes every 3 weeks for a maximum of 4 doses For the treatment of unresectable or metastatic melanoma in pediatric patients 12 years and older Colorectal Cancer 12 years and older: Ipilimumab 1 mg/kg IV over 30 minutes every 3 weeks with nivolumab 3 mg/kg IV over 30 minutes on the same day; after completing 4 doses of combination therapy, administer nivolumab as a single agent until disease progression or unacceptable toxicity Review the full prescribing information for nivolumab prior to initiation. In combination with nivolumab for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan in pediatric patients 12 years and older Dose Adjustments When ipilimumab is administered in combination with nivolumab, if ipilimumab is withheld, nivolumab should also be withheld. No dose reduction for ipilimumab is recommended: Withhold for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, persistent moderate (Grade 2) or severe (Grade 3) reactions lasting 12 weeks or longer after last dose (excluding endocrinopathy), or an inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks of initiating steroids. Dose modifications for ipilimumab or ipilimumab in combination with nivolumab for adverse reactions that require management different from these general guidelines are summarized below. IMMUNE-MEDIATED COLITIS: Grade 2: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 or 1) after corticosteroid taper; permanently discontinue if no complete or partial resolution within 12 weeks of last dose or inability to reduce prednisone to 10 mg per day (or equivalent) or less within 12 weeks of initiating steroids. Grade 3 or 4: Permanently discontinue therapy. IMMUNE-RELATED HEPATITIS: HEPATITIS WITH NO TUMOR INVOLVEMENT OF THE LIVER: AST or ALT increases to more than 3 times and up to 5 times the upper limit of normal (ULN) OR total bilirubin increases to more than 1.5 and up to 3 x ULN: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 or 1) after corticosteroid taper; permanently discontinue if no complete or partial resolution within 12 weeks of last dose or inability to reduce prednisone to 10 mg per day (or equivalent) or less within 12 weeks of initiating steroids OR HEPATITIS WITH TUMOR INVOLVEMENT OF THE LIVER/NON-HCC: AST or ALT more than 1.5 and up to 3 x ULN OR total bilirubin more than 3 x ULN: Permanently discontinue therapy. HEPATITIS WITH TUMOR INVOLVEMENT OF THE LIVER/HCCC: Baseline AST/ALT is more than 1 and up to 3 x ULN and increases to more than 5 and up to 10 x ULN OR baseline AST/ALT is more than 3 and up to 5 x ULN and increases to more than 8 and up to 10 x ULN: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 or 1) after corticosteroid taper; permanently discontinue if no complete or partial resolution within 12 weeks of last dose or inability to reduce prednisone to 10 mg per day (or equivalent) or less within 12 weeks of initiating steroids. AST/ALT increases to more than 10 x ULN OR total bilirubin increases to more than 3 x ULN: Permanently discontinue therapy. IMMUNE-MEDIATED EXFOLIATIVE DERMATOLOGIC CONDITIONS: Suspected Stevens Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), or drug rash with eosinophilia and systemic symptoms (DRESS): Withhold therapy. Confirmed SJS, TEN, or DRESS: Permanently discontinue therapy. IMMUNE-RELATED ENDOCRINOPATHIES (Depending on severity, consider withholding for Grade 2 endocrinopathy until symptom improvement with hormone replacement; resume once acute symptoms have resolved): Grade 3 or 4: Withhold therapy until stable or permanently discontinue depending on severity. IMMUNE-RELATED PNEUMONITIS: Grade 2: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 or 1) after corticosteroid taper; permanently discontinue if no complete or partial resolution within 12 weeks of last dose or inability to reduce prednisone to 10 mg per day (or equivalent) or less within 12 weeks of initiating steroids. Grade 3 or 4: Permanently discontinue therapy. IMMUNE-RELATED NEPHRITIS WITH RENAL DYSFUNCTION: Grade 2 or 3 increased blood creatinine: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 or 1) after corticosteroid taper; permanently discontinue if no complete or partial resolution within 12 weeks of last dose or inability to reduce prednisone to 10 mg per day (or equivalent) or less within 12 weeks of initiating steroids. Grade 3 or 4 increased blood creatinine: Permanently discontinue therapy. IMMUNE-RELATED NEUROLOGICAL TOXICITIES: Grade 2: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 or 1) after corticosteroid taper; permanently discontinue if no complete or partial resolution within 12 weeks of last dose or inability to reduce prednisone to 10 mg per day (or equivalent) or less within 12 weeks of initiating steroids. Grade 2: Withhold therapy; resume in patients with complete or partial resolution (Grade 0 or 1) after corticosteroid taper; permanently discontinue if no complete or partial resolution within 12 weeks of last dose or inability to reduce prednisone to 10 mg per day (or equivalent) or less within 12 weeks of initiating steroids. Grade 3 or 4: Permanently discontinue therapy. IMMUNE-RELATED MYOCARDITIS: Grade 2, 3, or 4: Permanently discontinue therapy. IMMUNE-RELATED OPHTHALMOLOGIC: Grade 2, 3, or 4 that does not improve to Grade 1 within 2 weeks while receiving topical therapy or that requires systemic treatment: Permanently discontinue therapy. IMMUNE-RELATED INFUSION REACTIONS: Grade 1 or 2: Interrupt or slow the rate of infusion. Grade 3 or 4: Permanently discontinue therapy. Consult the manufacturer product information and/or local protocol for information on corticosteroid therapy.Administration advice: This drug should be administered via an IV infusion over 90 minutes. It should not be administered as an IV push or bolus injection. An in-line, sterile, non-pyrogenic, low protein binding filter must be used for IV administration. A separate infusion line should be used for infusion; it should not be infused concomitantly in the same IV line with another drug. The line must be flushed with sterile 0.9% sodium chloride solution for injection at the end of infusion Any signs or symptoms which may indicate immune-related adverse events should be immediately reported; patients should not treat symptoms of these reactions with over-the-counter medications without consulting a health care provider. Patients should be advised to use caution when driving or operating machinery until they are certain that the drug does not adversely affect them. Side Effects The Most Common difficulty falling asleep or staying asleep joint pain decreased urination, blood in urine, swelling of feet, ankles, or lower legs, or loss of appetite diarrhea, bloody or black, tarry, sticky stools, severe stomach pain or tenderness, or fever cough, chest pain, or shortness of breath tiredness, confusion, memory problems, hallucinations, seizures, or stiff neck feeling tired, increased appetite, increased thirst, increased urination, or weight loss rapid heartbeat, uncontrollable shaking of a part of the body or sweating fatigue or sluggishness, increased sensitivity to cold, constipation, muscle ache and weakness, weight gain, heavier than normal or irregular menstrual periods, thinning hair, headache, dizziness, irritability, forgetfulness, decreased sex drive, or depression yellowing of skin or eyes, dark (tea-colored) urine, pain in upper right part of the stomach, nausea, vomiting, or easy bruising or bleeding unusual weakness of legs, arms, or face; or numbness or tingling in hands or feet rash with or without itching, blistering or peeling skin, or mouth sores blurred vision, double vision, eye pain or redness, or other vision problems More common Bloody, black, or tarry stools bone pain chest pain or tightness constipation cough depressed mood diarrhea dry skin and hair feeling cold fever hair loss heartburn hoarseness or husky voice indigestion itching, skin rash muscle cramps nausea pain in the arms or legs severe stomach pain, cramping, or burning slowed heartbeat sneezing sore throat trouble breathing unusual tiredness or weakness vomiting vomiting of material that looks like coffee grounds, severe and continuing watery or bloody diarrhea Rare Blistering, crusting, irritation, itching, or reddening of the skin bloody or cloudy urine blurred vision or other changes in vision burning, dry, or itching eyes burning, tingling, numbness or pain in the hands, arms, feet, or legs chills clay-colored stools cracked, dry, or scaly skin dark urine darkening of the skin decreased appetite decreased frequency or amount of urine difficulty with breathing, chewing, swallowing, or talking dizziness double vision drooping eyelids drowsiness eye discharge or excessive tearing eye pain or sensitivity to light fainting headache, possibly severe hives or welts loss of appetite mental depression muscle weakness pain, itching, burning, swelling, bleeding, or a lump under the skin where the needle was placed painful or difficult urination redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid sensation of pins and needles severe tiredness sores, ulcers, or white spots on the lips or in the mouth stabbing pain stomach tenderness swelling of the face, feet, or lower legs swollen glands unusual bleeding or bruising unusual weight gain yellow eyes or skin Anxiety bloating blue or pale skin chest pain, possibly moving to the left arm, neck, or shoulder confusion difficulty with moving fast heartbeat general feeling of discomfort or illness increased thirst lower back or side pain muscle pain, stiffness, or weakness pain or burning in the throat pain, swelling, or redness in the joints pains in the stomach or side, possibly radiating to the back skin irritation or rash, including rash that looks like psoriasis sores, welts, or blisters on the skin stiff neck or back Drug Interaction DRUG INTERACTION Abacavir Abacavir may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Ipilimumab. Aceclofenac Aceclofenac may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Acetaminophen Acetaminophen may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Aclidinium Ipilimumab may decrease the excretion rate of Aclidinium which could result in a higher serum level. Acrivastine Ipilimumab may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acyclovir Acyclovir may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Ipilimumab. Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Aducanumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Aducanumab. Albutrepenonacog Ipilimumab may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level. Alclofenac Alclofenac may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Aldesleukin Aldesleukin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ipilimumab. Alirocumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Alirocumab. Allopurinol Allopurinol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Almasilate Ipilimumab may decrease the excretion rate of Almasilate which could result in a higher serum level. Almotriptan Almotriptan may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Alogliptin Ipilimumab may decrease the excretion rate of Alogliptin which could result in a higher serum level. Alprazolam Alprazolam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Amantadine Amantadine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Amikacin Ipilimumab may decrease the excretion rate of Amikacin which could result in a higher serum level. Amiloride Amiloride may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Aminophenazone Aminophenazone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Amitriptyline Amitriptyline may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Amivantamab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Amivantamab. Ammonium chloride Ipilimumab may decrease the excretion rate of Ammonium chloride which could result in a higher serum level. Amoxicillin Amoxicillin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Amphetamine Amphetamine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Amphotericin B Amphotericin B may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ampicillin Ampicillin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Amrinone Amrinone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ancestim Ipilimumab may decrease the excretion rate of Ancestim which could result in a higher serum level. Anifrolumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Anifrolumab. Ansuvimab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Ansuvimab. Anthrax immune gl The risk or severity of adverse effects can be increased when Ipilimumab is combined with Anthrax immune globulin human. Antihemophilic Ipilimumab may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level. Antilymphocyte im The risk or severity of adverse effects can be increased when Ipilimumab is combined with Antilymphocyte immunoglobulin (horse). Antipyrine Antipyrine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Antithrombin Ipilimumab may decrease the excretion rate of Antithrombin III human which could result in a higher serum level. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ipilimumab. Antrafenine Antrafenine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Apalutamide Ipilimumab may decrease the excretion rate of Apalutamide which could result in a higher serum level. Apremilast Apremilast may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Arformoterol Arformoterol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Arsenic trioxide Arsenic trioxide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Articaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Articaine. Asfotase alfa The risk or severity of adverse effects can be increased when Ipilimumab is combined with Asfotase alfa. Atazanavir Atazanavir may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Atezolizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Atezolizumab. Atoltivimab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Atoltivimab. Atomoxetine Atomoxetine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Auranofin Auranofin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Aurothioglucose Ipilimumab may decrease the excretion rate of Aurothioglucose which could result in a higher serum level. Avelumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Avelumab. Azacitidine Azacitidine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Azathioprine Azathioprine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Azelaic acid Azelaic acid may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Aztreonam Aztreonam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Bacitracin Bacitracin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Baclofen Baclofen may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Balsalazide Balsalazide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Bamlanivimab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Bamlanivimab. Baricitinib Ipilimumab may decrease the excretion rate of Baricitinib which could result in a higher serum level. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Ipilimumab. Belantamab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Belantamab mafodotin. Belimumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Belimumab. Bendroflumethiazide Bendroflumethiazide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Benorilate Benorilate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Benoxaprofen Benoxaprofen may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Benralizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Benralizumab. Benserazide Ipilimumab may decrease the excretion rate of Benserazide which could result in a higher serum level. Benzatropine Benzatropine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Benznidazole Ipilimumab may decrease the excretion rate of Benznidazole which could result in a higher serum level. Benzocaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Benzocaine. Benzthiazide Benzthiazide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Benzydamine Benzydamine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Benzyl alcohol. Bepotastine Bepotastine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Besilesomab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Besilesomab. Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ipilimumab. Bezlotoxumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Bezlotoxumab. Bicisate Ipilimumab may decrease the excretion rate of Bicisate which could result in a higher serum level. Bimekizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Bimekizumab. Bismuth subgallate Ipilimumab may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level. Bisoprolol Bisoprolol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Bisoxatin Ipilimumab may decrease the excretion rate of Bisoxatin which could result in a higher serum level. Bleomycin Bleomycin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Blinatumomab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Blinatumomab. Brentuximab v The risk or severity of adverse effects can be increased when Ipilimumab is combined with Brentuximab vedotin. Brivaracetam Brivaracetam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Brodalumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Brodalumab. Brolucizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Brolucizumab. Bromazepam Bromazepam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Bromotheophylline Bromotheophylline may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Budesonide Budesonide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Bumadizone Bumadizone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Bumetanide Bumetanide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Bupivacaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Bupivacaine. Bupropion Bupropion may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Burosumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Burosumab. Buspirone Buspirone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Butabarbital Butabarbital may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Butacaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Butamben. Canagliflozin Canagliflozin may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Canakinumab The risk or severity of adverse effects can be increased when Canakinumab is combined with Ipilimumab. Canrenoic acid Canrenoic acid may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Capecitabine Capecitabine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ipilimumab. Capreomycin Ipilimumab may decrease the excretion rate of Capreomycin which could result in a higher serum level. Capromab pend The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ipilimumab. Capsaicin The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Capsaicin. Carbamazepine Ipilimumab may decrease the excretion rate of Carbamazepine which could result in a higher serum level. Carbidopa Carbidopa may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Carboplatin Carboplatin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Carmustine Carmustine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Carprofen Carprofen may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Casirivimab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Casirivimab. Catumaxomab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Catumaxomab. Cefaclor Cefaclor may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefadroxil Cefadroxil may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefalotin Cefalotin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefamandole Cefamandole may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefapirin Cefapirin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefazolin Cefazolin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefdinir Cefdinir may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefditoren Cefditoren may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefepime Cefepime may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefmenoxime Cefmenoxime may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefmetazole Cefmetazole may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefonicid Cefonicid may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefoperazone Cefoperazone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ceforanide Ceforanide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefotaxime Cefotaxime may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefotetan Cefotetan may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefotiam Cefotiam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefoxitin Cefoxitin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefpiramide Cefpiramide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefpirome Cefpirome may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefpodoxime Cefpodoxime may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefprozil Cefprozil may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefradine Cefradine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ceftaroline fos Ceftaroline fosamil may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ceftazidime Ceftazidime may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ceftibuten Ceftibuten may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ceftizoxime Ceftizoxime may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ceftobiprole Ceftobiprole may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ceftolozane Ipilimumab may decrease the excretion rate of Ceftolozane which could result in a higher serum level. Ceftriaxone Ceftriaxone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cefuroxime Cefuroxime may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Celecoxib Celecoxib may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cemiplimab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Cemiplimab. Cephalexin Cephalexin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cephaloglycin Cephaloglycin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Certolizumab p The risk or severity of adverse effects can be increased when Ipilimumab is combined with Certolizumab pegol. Cetirizine Cetirizine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ipilimumab. Cevimeline Cevimeline may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Chloral hydrate Chloral hydrate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Chloroprocaine. Chloroquine Chloroquine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Chlorothiazide Chlorothiazide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Chloroxylenol Ipilimumab may decrease the excretion rate of Chloroxylenol which could result in a higher serum level. Chlorpromazine Chlorpromazine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Chlorpropamide Chlorpropamide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Chlorthalidone Chlorthalidone may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Chlorzoxazone Chlorzoxazone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Choline C 11 Ipilimumab may decrease the excretion rate of Choline C 11 which could result in a higher serum level. Choline m Choline magnesium trisalicylate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Choline salicylate Ipilimumab may decrease the excretion rate of Choline salicylate which could result in a higher serum level. Chondroitin sulfate Ipilimumab may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level. Chromic chloride Ipilimumab may decrease the excretion rate of Chromic chloride which could result in a higher serum level. Chromic nitrate Ipilimumab may decrease the excretion rate of Chromic nitrate which could result in a higher serum level. Chromium Ipilimumab may decrease the excretion rate of Chromium which could result in a higher serum level. Chromium gl Ipilimumab may decrease the excretion rate of Chromium gluconate which could result in a higher serum level. Chromium nicot Ipilimumab may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level. Chromous sulfate Ipilimumab may decrease the excretion rate of Chromous sulfate which could result in a higher serum level. Cidofovir Cidofovir may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cilgavimab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Cilgavimab. Cilostazol Cilostazol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cimetidine Cimetidine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cinchocaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Cinchocaine. Ciprofloxacin Ciprofloxacin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cisplatin Ipilimumab may decrease the excretion rate of Cisplatin which could result in a higher serum level. Clevidipine Clevidipine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Clobazam Clobazam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Clofarabine Clofarabine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Clomipramine Clomipramine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Clonazepam Clonazepam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Clorazepic acid Clorazepic acid may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Clove oil Ipilimumab may decrease the excretion rate of Clove oil which could result in a higher serum level. Clozapine Clozapine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cocaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Cocaine. Colchicine Colchicine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Colistimethate Colistimethate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Colistin Ipilimumab may decrease the excretion rate of Colistin which could result in a higher serum level. Conivaptan Conivaptan may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Conj estroge Conjugated estrogens may increase the thrombogenic activities of Ipilimumab. Corifollitropin alfa Ipilimumab may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level. Cyanocobalamin Cyanocobalamin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cyclopenthiazide Cyclopenthiazide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Cyclosporine Cyclosporine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Cyclothiazide Cyclothiazide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Dabigatran ete Ipilimumab may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level. Dacarbazine Dacarbazine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Dalfampridine Ipilimumab may decrease the excretion rate of Dalfampridine which could result in a higher serum level. Dapagliflozin Dapagliflozin may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Daptomycin Daptomycin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Daratumumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Daratumumab. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Ipilimumab. Deferiprone Ipilimumab may decrease the excretion rate of Deferiprone which could result in a higher serum level. Delafloxacin Ipilimumab may decrease the excretion rate of Delafloxacin which could result in a higher serum level. Denosumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Denosumab. Desipramine Desipramine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Desmopressin Desmopressin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Desvenlafaxine Ipilimumab may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level. Deutetrabenazine Ipilimumab may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level. Dexibuprofen Dexibuprofen may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Dexketoprofen Dexketoprofen may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Dexmedetomidine Dexmedetomidine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Dexpanthenol Ipilimumab may decrease the excretion rate of Dexpanthenol which could result in a higher serum level. Dexrazoxane Dexrazoxane may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Dextran Ipilimumab may decrease the excretion rate of Dextran which could result in a higher serum level. Diatrizoate Diatrizoate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Diazepam Diazepam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Dichlorobenzyl al Ipilimumab may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level. Diclofenac Diclofenac may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Diclofenamide Diclofenamide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Dicyclomine Dicyclomine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Didanosine Didanosine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Dienestrol Dienestrol may increase the thrombogenic activities of Ipilimumab. Dienogest Ipilimumab may decrease the excretion rate of Dienogest which could result in a higher serum level. Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Ipilimumab. Diflunisal Diflunisal may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Difluocortolone Ipilimumab may decrease the excretion rate of Difluocortolone which could result in a higher serum level. Digoxin Ipilimumab may decrease the excretion rate of Digoxin which could result in a higher serum level. Digoxin Immune The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ipilimumab. Dihydrostreptomycin Dihydrostreptomycin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Dimercaprol Ipilimumab may decrease the excretion rate of Dimercaprol which could result in a higher serum level. Dimethyl sulfoxide Dimethyl sulfoxide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Dinutuximab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Dinutuximab. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Diphenhydramine. Disopyramide Disopyramide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. DL-Methylephed Ipilimumab may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level. Dobutamine Dobutamine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Dopamine Dopamine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Doripenem Ipilimumab may decrease the excretion rate of Doripenem which could result in a higher serum level. Dostarlimab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Dostarlimab. Doxacurium Doxacurium may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Doxepin Doxepin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Doxycycline Doxycycline may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Drospirenone Drospirenone may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Droxidopa Ipilimumab may decrease the excretion rate of Droxidopa which could result in a higher serum level. Dulaglutide The risk or severity of adverse effects can be increased when Ipilimumab is combined with Dulaglutide. Duloxetine Duloxetine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Dupilumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Dupilumab. Durvalumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Durvalumab. Dyclonine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Dyclonine. Dyphylline Dyphylline may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ebola Zaire vaccine The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Ipilimumab. Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Ipilimumab. Edoxaban Ipilimumab may decrease the excretion rate of Edoxaban which could result in a higher serum level. Edrophonium Edrophonium may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Ipilimumab. Eflapegrastim The risk or severity of adverse effects can be increased when Ipilimumab is combined with Eflapegrastim. Eftrenonacog alfa The risk or severity of adverse effects can be increased when Ipilimumab is combined with Eftrenonacog alfa. Elotuzumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Elotuzumab. Emapalumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Emapalumab. Emicizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Emicizumab. Enalaprilat Ipilimumab may decrease the excretion rate of Enalaprilat which could result in a higher serum level. Enzalutamide Ipilimumab may decrease the excretion rate of Enzalutamide which could result in a higher serum level. Eplerenone Eplerenone may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Epoprostenol Epoprostenol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Eptinezumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Eptinezumab. Erenumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Erenumab. Ertapenem Ertapenem may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ertugliflozin Ertugliflozin may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Ipilimumab. Estazolam Estazolam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Ipilimumab. Estetrol Estetrol may increase the thrombogenic activities of Ipilimumab. Estradiol Estradiol may increase the thrombogenic activities of Ipilimumab. Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Ipilimumab. Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Ipilimumab. Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Ipilimumab. Estradiol dienan Ipilimumab may decrease the excretion rate of Estradiol dienanthate which could result in a higher serum level. Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Ipilimumab. Estriol Estriol may increase the thrombogenic activities of Ipilimumab. Estrone Estrone may increase the thrombogenic activities of Ipilimumab. Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Ipilimumab. Eszopiclone Eszopiclone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Etacrynic acid Etacrynic acid may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Etafedrine Ipilimumab may decrease the excretion rate of Etafedrine which could result in a higher serum level. Ethambutol Ethambutol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Ipilimumab. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Etidocaine. Etodolac Etodolac may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Etomidate Etomidate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Etonogestrel Etonogestrel may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Etoricoxib Etoricoxib may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Eucalyptus oil Ipilimumab may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level. Evolocumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Evolocumab. Ezogabine Ezogabine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Fanolesomab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Fanolesomab. Fenbufen Fenbufen may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Fenofibrate Fenofibrate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Fenofibric acid Ipilimumab may decrease the excretion rate of Fenofibric acid which could result in a higher serum level. Fenoldopam Fenoldopam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Fenoprofen Fenoprofen may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Fentanyl Fentanyl may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Fesoterodine Ipilimumab may decrease the excretion rate of Fesoterodine which could result in a higher serum level. Finerenone Finerenone may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Flavoxate Flavoxate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Floctafenine Floctafenine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Florbetaben (18F) Ipilimumab may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level. Florbetapir Ipilimumab may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level. Floxuridine Floxuridine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Fluconazole Fluconazole may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Flucytosine Flucytosine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Fludeoxyglucose Ipilimumab may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level. Flumazenil Flumazenil may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Fluocinolone ace Fluocinolone acetonide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Flurazepam Flurazepam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Flurbiprofen Flurbiprofen may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Flutamide Flutamide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Fluvoxamine Fluvoxamine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Folic acid Folic acid may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Fomepizole Fomepizole may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Fondaparinux Fondaparinux may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Formestane Ipilimumab may decrease the excretion rate of Formestane which could result in a higher serum level. Foscarnet Foscarnet may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Fosfomycin Fosfomycin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Fosinopril Fosinopril may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Framycetin Framycetin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Fremanezumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Fremanezumab. Furosemide Furosemide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Gabapentin enac Ipilimumab may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level. Gadobenic acid Gadobenic acid may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Gadodiamide Gadodiamide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Gadofosveset tri Ipilimumab may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level. Gadopentetic acid Gadopentetic acid may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Gadoteric acid Ipilimumab may decrease the excretion rate of Gadoteric acid which could result in a higher serum level. Gadoteridol Gadoteridol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Galcanezumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Galcanezumab. Ganciclovir Ganciclovir may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Gemcitabine Gemcitabine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Gemfibrozil Gemfibrozil may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Gemtuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ipilimumab. Gentamicin Ipilimumab may decrease the excretion rate of Gentamicin which could result in a higher serum level. Gimeracil Ipilimumab may decrease the excretion rate of Gimeracil which could result in a higher serum level. Givosiran Givosiran may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Glipizide Glipizide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Glycerol phenyl Ipilimumab may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level. Golimumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Golimumab. Golodirsen Ipilimumab may decrease the excretion rate of Golodirsen which could result in a higher serum level. Goserelin Goserelin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Guanethidine Guanethidine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Guanfacine Guanfacine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Guselkumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Guselkumab. Haloperidol Haloperidol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Hepatitis B The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Ipilimumab. Hu cytomegalovirus The risk or severity of adverse effects can be increased when Ipilimumab is combined with Human cytomegalovirus immune globulin. H immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ipilimumab. Hu immune globulin The risk or severity of adverse effects can be increased when Ipilimumab is combined with Human Rho(D) immune globulin. Human varicella The risk or severity of adverse effects can be increased when Ipilimumab is combined with Human varicella-zoster immune globulin. Hydralazine Hydralazine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Hydrochlorothiazide Hydrochlorothiazide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Hydroflumethiazide Hydroflumethiazide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Hydromorphone Hydromorphone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Hydroxocobalamin Hydroxocobalamin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Hydroxyethyl Starch Ipilimumab may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level. Ibalizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Ibalizumab. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ipilimumab. Ibuprofen Ibuprofen may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ibutilide Ibutilide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Icatibant Ipilimumab may decrease the excretion rate of Icatibant which could result in a higher serum level. Icosapent Icosapent may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Idarucizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Idarucizumab. Idebenone Ipilimumab may decrease the excretion rate of Idebenone which could result in a higher serum level. Ifosfamide Ifosfamide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Imdevimab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Imdevimab. Imipramine Imipramine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Imlifidase The therapeutic efficacy of Ipilimumab can be decreased when used in combination with Imlifidase. Indapamide Indapamide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Indigotindisulfonic Ipilimumab may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level. Indomethacin Indomethacin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Inebilizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Inebilizumab. Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Ipilimumab. Inosine pranobex Ipilimumab may decrease the excretion rate of Inosine pranobex which could result in a higher serum level. Inositol Ipilimumab may decrease the excretion rate of Inositol which could result in a higher serum level. Inotersen Inotersen may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Inotuzumab The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ipilimumab. Iobenguane su Ipilimumab may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level. Iodixanol Iodixanol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ioflupane I-123 Ipilimumab may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level. Iopromide Ipilimumab may decrease the excretion rate of Iopromide which could result in a higher serum level. Iothalamic acid Ipilimumab may decrease the excretion rate of Iothalamic acid which could result in a higher serum level. Ioversol Ipilimumab may decrease the excretion rate of Ioversol which could result in a higher serum level. Ioxilan Ipilimumab may decrease the excretion rate of Ioxilan which could result in a higher serum level. Ipecac Ipilimumab may decrease the excretion rate of Ipecac which could result in a higher serum level. Isatuximab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Isatuximab. Isoniazid Isoniazid may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Isosorbide Isosorbide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Isosorbide mo Isosorbide mononitrate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Isosulfan blue Ipilimumab may decrease the excretion rate of Isosulfan blue which could result in a higher serum level. Isotretinoin Isotretinoin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Isoxicam Isoxicam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Isradipine Isradipine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ixazomib Ipilimumab may decrease the excretion rate of Ixazomib which could result in a higher serum level. Ixekizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Ixekizumab. Kanamycin Ipilimumab may decrease the excretion rate of Kanamycin which could result in a higher serum level. Ketamine Ketamine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ketazolam Ketazolam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ketoprofen Ketoprofen may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ketorolac Ketorolac may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Labetalol Labetalol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Lamivudine Lamivudine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Lamotrigine Lamotrigine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Lanadelumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Lanadelumab. Latamoxef Latamoxef may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Lecanemab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Lecanemab. Ledipasvir Ipilimumab may decrease the excretion rate of Ledipasvir which could result in a higher serum level. Lenalidomide Lenalidomide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Lesinurad Ipilimumab may decrease the excretion rate of Lesinurad which could result in a higher serum level. Leuprolide Leuprolide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Levobupivacaine. Levocarnitine Levocarnitine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Levocetirizine Ipilimumab may decrease the excretion rate of Levocetirizine which could result in a higher serum level. Levofloxacin Levofloxacin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Levomilnacipran Ipilimumab may decrease the excretion rate of Levomilnacipran which could result in a higher serum level. Levosalbutamol Ipilimumab may decrease the excretion rate of Levosalbutamol which could result in a higher serum level. Lidocaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Lidocaine. Liothyronine Liothyronine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Lisinopril Lisinopril may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Lithium carbonate Ipilimumab may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. Lithium citrate Lithium citrate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Lixisenatide Ipilimumab may decrease the excretion rate of Lixisenatide which could result in a higher serum level. Lofexidine Lofexidine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Loncastuximab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Loncastuximab tesirine. Lopinavir Lopinavir may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Loracarbef Loracarbef may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Lorazepam Lorazepam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Lorcaserin Lorcaserin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Lornoxicam Lornoxicam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Lorpiprazole Ipilimumab may decrease the excretion rate of Lorpiprazole which could result in a higher serum level. Loxoprofen Loxoprofen may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Lubiprostone Lubiprostone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Lumiracoxib Lumiracoxib may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Macitentan Ipilimumab may decrease the excretion rate of Macitentan which could result in a higher serum level. Maftivimab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Maftivimab. Magnesium car Ipilimumab may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level. Magnesium chl Ipilimumab may decrease the excretion rate of Magnesium chloride which could result in a higher serum level. Magnesium hydr Ipilimumab may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level. Magnesium trisili Ipilimumab may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level. Mangafodipir Ipilimumab may decrease the excretion rate of Mangafodipir which could result in a higher serum level. Mannitol Mannitol may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Maprotiline Maprotiline may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Margetuximab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Margetuximab. Mecamylamine Mecamylamine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Meclofenamic acid Meclofenamic acid may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Medroxyprogester Medroxyprogesterone acetate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Mefenamic acid Mefenamic acid may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Megestrol acetate Megestrol acetate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Meloxicam The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Meloxicam. Memantine Memantine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Meperidine Meperidine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Mepivacaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Mepolizumab. Meropenem Meropenem may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Mesalazine Mesalazine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Mestranol Mestranol may increase the thrombogenic activities of Ipilimumab. Metamfetamine Metamfetamine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Metamizole Metamizole may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Metaxalone Metaxalone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Metformin Metformin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Methadone Methadone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Methazolamide Methazolamide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Methimazole Methimazole may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Methotrexate Methotrexate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Methoxsalen Methoxsalen may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Methoxy po The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Ipilimumab. Methyldopa Methyldopa may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Methylene blue Ipilimumab may decrease the excretion rate of Methylene blue which could result in a higher serum level. Methylnaltrexone Ipilimumab may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level. Methyltestosterone Ipilimumab may decrease the excretion rate of Methyltestosterone which could result in a higher serum level. Meticrane Meticrane may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Metoclopramide Metoclopramide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Metolazone Metolazone may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Metoprolol Metoprolol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Metyrapone Metyrapone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Midazolam Midazolam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Migalastat Migalastat may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Milnacipran Milnacipran may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Milrinone Milrinone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Mirabegron Ipilimumab may decrease the excretion rate of Mirabegron which could result in a higher serum level. Mogamulizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Mogamulizumab. Mosunetuzumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Mosunetuzumab. Moxisylyte Ipilimumab may decrease the excretion rate of Moxisylyte which could result in a higher serum level. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Ipilimumab. Muzolimine Muzolimine may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Mycophenolate Mycophenolate mofetil may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Mycophenolic acid Mycophenolic acid may decrease the excretion rate of Ipilimumab which could result in a higher serum level. N-acetyltyrosine Ipilimumab may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level. Nabumetone Nabumetone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Nadolol Nadolol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Naldemedine Ipilimumab may decrease the excretion rate of Naldemedine which could result in a higher serum level. Nalmefene Ipilimumab may decrease the excretion rate of Nalmefene which could result in a higher serum level. Naloxone Naloxone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Naproxen Naproxen may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Ipilimumab. Nateglinide Nateglinide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Necitumumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Necitumumab. Nedaplatin Ipilimumab may decrease the excretion rate of Nedaplatin which could result in a higher serum level. Nedocromil Nedocromil may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Nefazodone Nefazodone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Neomycin Ipilimumab may decrease the excretion rate of Neomycin which could result in a higher serum level. Netilmicin Ipilimumab may decrease the excretion rate of Netilmicin which could result in a higher serum level. Nicorandil Ipilimumab may decrease the excretion rate of Nicorandil which could result in a higher serum level. Nifedipine Nifedipine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Nilutamide Nilutamide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Nimesulide Nimesulide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Nisoldipine Nisoldipine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Nitric Oxide Nitric Oxide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Nitrofurantoin Nitrofurantoin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Nitroprusside Nitroprusside may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Nivolumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Nivolumab. Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Ipilimumab. Obinutuzumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Obinutuzumab. Ocrelizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Ocrelizumab. Octinoxate Ipilimumab may decrease the excretion rate of Octinoxate which could result in a higher serum level. Odesivimab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Odesivimab. Ofatumumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Ofatumumab. Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Ipilimumab. Olsalazine Olsalazine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ipilimumab. Opium Ipilimumab may decrease the excretion rate of Opium which could result in a higher serum level. Oseltamivir Oseltamivir may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Oxacillin Oxacillin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Oxaprozin Oxaprozin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Oxazepam Oxazepam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Oxetacaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Oxetacaine. Oxybenzone Oxybenzone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Oxybuprocaine. Oxyphenbutazone Oxyphenbutazone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Oxyquinoline Ipilimumab may decrease the excretion rate of Oxyquinoline which could result in a higher serum level. Paliperidone Paliperidone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Ipilimumab. Palonosetron Palonosetron may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Pamidronic acid Pamidronic acid may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Ipilimumab. Pantoprazole Pantoprazole may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Parecoxib Parecoxib may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Paromomycin Paromomycin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Patent Blue Ipilimumab may decrease the excretion rate of Patent Blue which could result in a higher serum level. Pegaptanib Pegaptanib may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Ipilimumab. Pembrolizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Pembrolizumab. Pemetrexed Ipilimumab may decrease the excretion rate of Pemetrexed which could result in a higher serum level. Penbutolol Penbutolol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Pentaerythritol t Pentaerythritol tetranitrate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Pentamidine Pentamidine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Pentastarch Ipilimumab may decrease the excretion rate of Pentastarch which could result in a higher serum level. Pentetic acid Ipilimumab may decrease the excretion rate of Pentetic acid which could result in a higher serum level. Pentobarbital Pentobarbital may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Pentostatin Ipilimumab may decrease the excretion rate of Pentostatin which could result in a higher serum level. Pentoxifylline Pentoxifylline may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Perindopril Perindopril may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Permethrin Permethrin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Pertuzumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Pertuzumab. Phenazopyridine Phenazopyridine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Phenelzine Phenelzine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Phenol The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Phenol. Phentolamine Phentolamine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Phenylbutazone Phenylbutazone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Pholcodine Ipilimumab may decrease the excretion rate of Pholcodine which could result in a higher serum level. Phosphoric acid Ipilimumab may decrease the excretion rate of Phosphoric acid which could result in a higher serum level. Phylloquinone Phylloquinone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Picosulfuric acid Ipilimumab may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level. Pindolol Pindolol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Piperacillin Piperacillin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Piracetam Ipilimumab may decrease the excretion rate of Piracetam which could result in a higher serum level. Piretanide Piretanide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Piroxicam Piroxicam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Pitolisant Ipilimumab may decrease the excretion rate of Pitolisant which could result in a higher serum level. Plazomicin Ipilimumab may decrease the excretion rate of Plazomicin which could result in a higher serum level. Plerixafor Ipilimumab may decrease the excretion rate of Plerixafor which could result in a higher serum level. Polatuzumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Polatuzumab vedotin. Polyestradiol Polyestradiol phosphate may increase the thrombogenic activities of Ipilimumab. Polythiazide Polythiazide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Pomalidomide Ipilimumab may decrease the excretion rate of Pomalidomide which could result in a higher serum level. Potassium Potassium may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Potassium acetate Ipilimumab may decrease the excretion rate of Potassium acetate which could result in a higher serum level. Potassium bicar Ipilimumab may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level. Potassium cation Potassium cation may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Potassium chloride Potassium chloride may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Potassium citrate Potassium citrate may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Potassium nitrate Ipilimumab may decrease the excretion rate of Potassium nitrate which could result in a higher serum level. Potassium perc Ipilimumab may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level. Potassium sulfate Ipilimumab may decrease the excretion rate of Potassium sulfate which could result in a higher serum level. Pralatrexate Ipilimumab may decrease the excretion rate of Pralatrexate which could result in a higher serum level. Pralidoxime Pralidoxime may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Pramipexole Pramipexole may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Pramocaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Pramocaine. Prasugrel Ipilimumab may decrease the excretion rate of Prasugrel which could result in a higher serum level. Prednisone Prednisone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Pregabalin Pregabalin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Prilocaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Prilocaine. Probenecid Probenecid may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Procainamide Ipilimumab may decrease the excretion rate of Procainamide which could result in a higher serum level. Procaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Procaine. Procaine benz Ipilimumab may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level. Promethazine Promethazine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Propantheline Propantheline may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Proparacaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Proparacaine. Propiverine Ipilimumab may decrease the excretion rate of Propiverine which could result in a higher serum level. Propoxycaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Propoxycaine. Propranolol Propranolol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Prucalopride Ipilimumab may decrease the excretion rate of Prucalopride which could result in a higher serum level. Pyrantel Ipilimumab may decrease the excretion rate of Pyrantel which could result in a higher serum level. Pyrazinamide Pyrazinamide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Pyridoxine Pyridoxine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Pyrithione Ipilimumab may decrease the excretion rate of Pyrithione which could result in a higher serum level. Quetiapine Quetiapine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Quinestrol Quinestrol may increase the thrombogenic activities of Ipilimumab. Quinethazone Quinethazone may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Quinidine Ipilimumab may decrease the excretion rate of Quinidine which could result in a higher serum level. Rabeprazole Rabeprazole may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ramelteon Ramelteon may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Ipilimumab. Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Ipilimumab. Ranitidine Ranitidine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ranolazine Ranolazine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Rasagiline Rasagiline may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ravulizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Ravulizumab. Raxibacumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Raxibacumab. Reserpine Reserpine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Reslizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Reslizumab. Resorcinol Ipilimumab may decrease the excretion rate of Resorcinol which could result in a higher serum level. Ribavirin Ribavirin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ribostamycin Ipilimumab may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Risankizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Risankizumab. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Ipilimumab. Rivaroxaban Ipilimumab may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. Rizatriptan Rizatriptan may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Rofecoxib Rofecoxib may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Roflumilast Roflumilast may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Romosozumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Romosozumab. Ropivacaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Ropivacaine. Rosiglitazone Rosiglitazone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Ruxolitinib Ipilimumab may decrease the excretion rate of Ruxolitinib which could result in a higher serum level. Sacituzumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Sacituzumab govitecan. Sacubitril Ipilimumab may decrease the excretion rate of Sacubitril which could result in a higher serum level. Salbutamol Salbutamol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Salicylamide Salicylamide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Salicylic acid Salicylic acid may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Salmon calcitonin Salmon calcitonin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Salsalate Salsalate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Sarilumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Sarilumab. Saxagliptin Ipilimumab may decrease the excretion rate of Saxagliptin which could result in a higher serum level. Secobarbital Secobarbital may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Secukinumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Secukinumab. Selenious acid Ipilimumab may decrease the excretion rate of Selenious acid which could result in a higher serum level. Selenium Ipilimumab may decrease the excretion rate of Selenium which could result in a higher serum level. Sibutramine Sibutramine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Siltuximab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Siltuximab. Sitagliptin Sitagliptin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Sodium acetate Ipilimumab may decrease the excretion rate of Sodium acetate which could result in a higher serum level. Sodium aurothi Ipilimumab may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level. Sodium fluoride Ipilimumab may decrease the excretion rate of Sodium fluoride which could result in a higher serum level. Sodium sulfate Ipilimumab may decrease the excretion rate of Sodium sulfate which could result in a higher serum level. Sofosbuvir Ipilimumab may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. Solriamfetol Ipilimumab may decrease the excretion rate of Solriamfetol which could result in a higher serum level. Sorafenib Sorafenib may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Sorbitol Sorbitol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Sotrovimab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Sotrovimab. Spesolimab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Spesolimab. Spironolactone Spironolactone may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Stiripentol Ipilimumab may decrease the excretion rate of Stiripentol which could result in a higher serum level. Streptomycin Ipilimumab may decrease the excretion rate of Streptomycin which could result in a higher serum level. Strontium chloride Ipilimumab may decrease the excretion rate of Strontium chloride which could result in a higher serum level. Sucralfate Sucralfate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Sulbactam Ipilimumab may decrease the excretion rate of Sulbactam which could result in a higher serum level. Sulesomab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Sulesomab. Sulfadiazine Sulfadiazine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Sulfamethoxazole Sulfamethoxazole may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Sulfasalazine Sulfasalazine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Sulindac Sulindac may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Sumatriptan Sumatriptan may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Sutimlimab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Sutimlimab. S Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Ipilimumab. Syn Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ipilimumab. Tacrolimus Tacrolimus may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tadalafil Tadalafil may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tafasitamab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Tafasitamab. Tamsulosin Tamsulosin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tasimelteon Ipilimumab may decrease the excretion rate of Tasimelteon which could result in a higher serum level. Te exametazime Ipilimumab may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level. Tech mebrofenin Ipilimumab may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level. Tecoxidronate Ipilimumab may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level. Tech pyrophosphate Ipilimumab may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level. Teduglutide Ipilimumab may decrease the excretion rate of Teduglutide which could result in a higher serum level. Tegafur Ipilimumab may decrease the excretion rate of Tegafur which could result in a higher serum level. Telavancin Ipilimumab may decrease the excretion rate of Telavancin which could result in a higher serum level. Temazepam Temazepam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Temozolomide Temozolomide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tenofovir alafen The serum concentration of Tenofovir alafenamide can be increased when it is combined with Ipilimumab. Tenofovir disop Tenofovir disoproxil may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tenoxicam Tenoxicam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Teplizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Teplizumab. Terbutaline Terbutaline may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Testolactone Testolactone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Testosterone Testosterone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Testosterone Ipilimumab may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. Testosterone Ipilimumab may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. Testosterone pro Testosterone propionate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Testosterone Ipilimumab may decrease the excretion rate of Testosterone undecanoate which could result in a higher serum level. Tetanus immu The risk or severity of adverse effects can be increased when Ipilimumab is combined with Tetanus immune globulin, human. Tetracaine The risk or severity of methemoglobinemia can be increased when Ipilimumab is combined with Tetracaine. Tetracycline Tetracycline may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tetradecyl hydro Ipilimumab may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level. Tezepelumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Tezepelumab. Thiabendazole Thiabendazole may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Thiethylperazine Thiethylperazine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tiaprofenic acid Tiaprofenic acid may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tibolone Tibolone may increase the thrombogenic activities of Ipilimumab. Ticlopidine Ticlopidine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tildrakizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Tildrakizumab. Tiludronic acid Tiludronic acid may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Timolol Timolol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tinidazole Tinidazole may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tiopronin Ipilimumab may decrease the excretion rate of Tiopronin which could result in a higher serum level. Tiotropium Tiotropium may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tirofiban Tirofiban may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tisotumab vedotin The risk or severity of adverse effects can be increased when Ipilimumab is combined with Tisotumab vedotin. Tixagevimab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Tixagevimab. Tixocortol Ipilimumab may decrease the excretion rate of Tixocortol which could result in a higher serum level. Tobramycin Ipilimumab may decrease the excretion rate of Tobramycin which could result in a higher serum level. Tocilizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Tocilizumab. Tocopherol Ipilimumab may decrease the excretion rate of Tocopherol which could result in a higher serum level. Tolazamide Tolazamide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tolbutamide Tolbutamide may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tolcapone Tolcapone may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tolfenamic acid Tolfenamic acid may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tolmetin Tolmetin may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tolterodine Tolterodine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tolvaptan Tolvaptan may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Topiramate Topiramate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Topotecan Topotecan may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Torasemide Torasemide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Ipilimumab. Tralokinumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Tralokinumab. Tramadol Tramadol may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Trametinib Ipilimumab may decrease the excretion rate of Trametinib which could result in a higher serum level. Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ipilimumab. Trastuzumab der The risk or severity of adverse effects can be increased when Ipilimumab is combined with Trastuzumab deruxtecan. Trastuzumab emt The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Ipilimumab. Tremelimumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Tremelimumab. Triamterene Triamterene may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Triazolam Triazolam may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Trichlormethiazide Trichlormethiazide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Triethylenetetramine Ipilimumab may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level. Trifluridine Trifluridine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Trimebutine Ipilimumab may decrease the excretion rate of Trimebutine which could result in a higher serum level. Trimethoprim Trimethoprim may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Trimetrexate Trimetrexate may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Tropisetron Ipilimumab may decrease the excretion rate of Tropisetron which could result in a higher serum level. Ublituximab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Ublituximab. Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Ipilimumab. Vaborbactam Ipilimumab may decrease the excretion rate of Vaborbactam which could result in a higher serum level. Valaciclovir Valaciclovir may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Valbenazine Ipilimumab may decrease the excretion rate of Valbenazine which could result in a higher serum level. Valdecoxib Valdecoxib may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Valganciclovir Valganciclovir may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Vancomycin Ipilimumab may decrease the excretion rate of Vancomycin which could result in a higher serum level. Varenicline Varenicline may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Vedolizumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Vedolizumab. Vemurafenib Ipilimumab may increase the hepatotoxic activities of Vemurafenib. Venlafaxine Venlafaxine may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Verapamil Verapamil may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Vilanterol Ipilimumab may decrease the excretion rate of Vilanterol which could result in a higher serum level. Viloxazine Ipilimumab may decrease the excretion rate of Viloxazine which could result in a higher serum level. Vortioxetine Ipilimumab may decrease the excretion rate of Vortioxetine which could result in a higher serum level. Warfarin Ipilimumab may decrease the excretion rate of Warfarin which could result in a higher serum level. Zaleplon Zaleplon may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Zanamivir Zanamivir may decrease the excretion rate of Ipilimumab which could result in a higher serum level. Zonisamide Zonisamide may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy. Pregnancy and Lactation AU TGA pregnancy category: C US FDA pregnancy category: Not assigned Pregnancy Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology (12.1)], YERVOY can cause fetal harm when administered to a pregnant woman. There is insufficient human data for YERVOY exposure in pregnant women. In animal reproduction studies, administration of ipilimumab to cynomolgus monkeys from the onset of organogenesis through delivery resulted in higherincidences of abortion, stillbirth, premature delivery (with corresponding lower birth weight), and higher incidences of infant mortality in a dose-related manner (see Data). The effects of ipilimumab are likely to be greater during the second and third trimesters of pregnancy. Human IgG1 is known to cross the placental barrier and ipilimumab is an IgG1; therefore, ipilimumab has the potential to be transmitted from the mother to the developing fetus. Advise pregnant women of the potential risk to a fetus. Report pregnancies to Bristol-Myers Squibb at 1-844-593-7869. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Lactation There are no data on the presence of YERVOY in human milk or its effects on the breastfed child or milk production. In monkeys, ipilimumab was present in milk (see Data). Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with YERVOY and for 3 months following the last dose. Why is this medication prescribed? Ipilimumab injection is used: to treat melanoma (a type of skin cancer) in adults and children 12 years of age and older that cannot be treated with surgery or that has spread to other parts of the body. It is also used in combination with nivolumab (Opdivo) to treat melanoma in adults that cannot be treated with surgery or that has spread to other parts of the body. to treat and prevent the return of a certain type of melanoma after surgery to remove it and any affected lymph nodes. in combination with nivolumab to treat advanced renal cell carcinoma (RCC; a type of cancer that begins in the cells of the kidneys). in combination with nivolumab to treat certain types of colorectal cancer (cancer that begins in the large intestine) in adults and children 12 years of age and older that has spread to other parts of the body and has worsened after treatment with other chemotherapy medications. in combination with nivolumab to treat hepatocellular carcinoma (HCC; a type of liver cancer) in people who were previously treated with sorafenib (Nexafar). in combination with nivolumab to a certain type of lung cancer (non-small cell lung cancer; NSCLC) in adults that has spread to other parts of the body. in combination with nivolumab and platinum-containing chemotherapy to treat a certain type of NSCLC in adults that has returned or has spread to other parts of the body. in combination with nivolumab to treat malignant pleural mesothelioma (a type of cancer that affects the inside lining of the lungs and chest cavity) in adults that cannot be removed by surgery. and in combination with nivolumab to treat a certain type of esophageal cancer (cancer of the tube that connects your throat to your stomach) that has spread to other parts of the body or cannot be treated with surgery. Ipilimumab injection is in a class of medications called monoclonal antibodies. It works by helping the body to slow or stop the growth of cancer cells. How should this medicine be used? Ipilimumab injection comes as a solution (liquid) to be injected intravenously (into a vein) by a doctor or nurse in a hospital or medical facility. When ipilimumab is given alone to treat and help prevent the return of melanoma, it is usually given over 90 minutes once every 3 weeks for 4 doses and then once every 12 weeks as long as your doctor recommends that you receive treatment. When ipilimumab is given alone or along with nivolumab to treat melanoma, it is usually given over 30 minutes once every 3 weeks for up to 4 doses. When ipilimumab is given with nivolumab to treat renal cell carcinoma, hepatocellular carcinoma, or colorectal cancer, it is usually given over 30 minutes once every 3 weeks for up to 4 doses. When ipilimumab is given with nivolumab to treat malignant pleural mesothelioma or esophageal cancer or with nivolumab and platinum-containing chemotherapy to treat NSCLC, it is usually given over 30 minutes once every 6 weeks for as long as your doctor recommends that you receive treatment. Ipilimumab injection may cause serious or life-threatening reactions during an infusion. A doctor or nurse will watch you closely while you are receiving the infusion and shortly after the infusion to be sure you are not having a serious reaction to the medication. Tell your doctor or nurse immediately if you experience any of the following symptoms that may occur during the infusion: chills or shaking, itching, rash, flushing, difficulty breathing, dizziness, fever, or feeling faint. Your doctor may slow down your infusion, delay, or stop your treatment with ipilimumab injection, or treat you with additional medications depending on your response to the medication and any side effects that you experience. Talk to your doctor about how you are feeling during your treatment. Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with ipilimumab and each time you refill your prescription. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) or the manufacturer’s website to obtain the Medication Guide. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. What special precautions should I follow? Before receiving ipilimumab injection, tell your doctor and pharmacist if you are allergic to ipilimumab injection, any other medications, or any of the ingredients in ipilimumab injection. Ask your pharmacist or check the Medication Guide for a list of the ingredients. tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. tell your doctor if you have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic) or have ever had an organ transplant. Also, tell your doctor if you have or have ever had an autoimmune disease (condition in which the immune system attacks a healthy part of the body) such as Crohn’s disease (condition in which the immune system attacks the lining of the digestive tract causing pain, diarrhea, weight loss, and fever), ulcerative colitis (a condition which causes swelling and sores in the lining of the colon [large intestine] and rectum), lupus (a condition in which the immune system attacks many tissues and organs including the skin, joints, blood, and kidneys); any condition that affects your nervous system such as myasthenia gravis (a disorder of the nervous system that causes muscle weakness) or Guillain-Barré syndrome (weakness, tingling, and possible paralysis due to sudden nerve damage); thyroid problems; or liver disease. tell your doctor if you are pregnant or plan to become pregnant. You will need to take a pregnancy test before you receive ipilimumab. You should use effective birth control to prevent pregnancy during your treatment with ipilimumab injection and for 3 months after your final dose. Talk to your doctor about birth control methods that will work for you. If you become pregnant while receiving ipilimumab injection, call your doctor immediately. Ipilimumab injection may harm the fetus. tell your doctor if you are breastfeeding or plan to breastfeed. You should not breastfeed while receiving ipilimumab injection and for 3 months after your final dose. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125377s094lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125377s115lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125377s110lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125377s073lbl.pdf https://www.cancer.gov/about-cancer/treatment/drugs/ipilimumab https://pubchem.ncbi.nlm.nih.gov/patent/LU-91928-I2 https://pubchem.ncbi.nlm.nih.gov/patent/WO-2020214748-A1 https://www.ncbi.nlm.nih.gov/books/NBK557795/ https://medlineplus.gov/druginfo/meds/a611023.html https://www.drugs.com/ipilimumab.html https://go.drugbank.com/drugs/DB06186 https://en.wikipedia.org/wiki/Ipilimumab https://www.mayoclinic.org/drugs-supplements/ipilimumab-intravenous-route/side-effects/drg-20074841 https://creativecommons.org/licenses/by/4.0/legalcode https://patents.google.com/patent/WO2020214748A1 https://pubchem.ncbi.nlm.nih.gov References